Literature DB >> 10819574

Effective repeat administration with adenovirus vectors to the muscle.

P Chen1, I Kovesdi, J T Bruder.   

Abstract

Effective repeat administration of adenovirus vectors following intranasal or intravenous delivery is hindered by a strong neutralizing antibody response to the vector. Intramuscular administration of adenovirus vectors elicited a neutralizing antibody response that peaked between 14 and 21 days after infection. However, effective repeat intramuscular administration of adenovirus vectors was not hindered by the presence of neutralizing antibodies in the serum. Surprisingly, beta-galactosidase expression in the skeletal muscle of immunized mice was equivalent to that observed in control mice. As expected, these serum neutralizing antibodies effectively blocked repeat administration of adenovirus vectors when delivered via the intravenous route. These results were observed in both C57BL/6 and Balb/c mice and thus do not appear to be strain specific. Successful repeat administration of adenovirus vectors to skeletal muscle has significant implications for the use of adenovirus vectors clinically and for increasing the safety and efficacy of adenovirus vector gene delivery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819574     DOI: 10.1038/sj.gt.3301137

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) confers protection against hepatic fibrosis through downregulation of transforming growth factor β receptor II.

Authors:  Qian Li; Hanchao Li; Yifei Lv; Qiannan Zhang; Xueting Zhang; Shuang Li; Xiaoyan Zheng; Yanhua Wang; Zhiming Hao
Journal:  Lab Invest       Date:  2019-10-22       Impact factor: 5.662

5.  Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.

Authors:  Philip L Leopold; Rebecca L Wendland; Theresa Vincent; Ronald G Crystal
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

Authors:  K Tominaga; S Kuriyama; H Yoshiji; A Deguchi; Y Kita; F Funakoshi; T Masaki; K Kurokohchi; N Uchida; T Tsujimoto; H Fukui
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

7.  Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery.

Authors:  Li Li; Jia-Ling Huang; Qi-Cai Liu; Pei-Hong Wu; Ran-Yi Liu; Yi-Xin Zeng; Wen-Lin Huang
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

Review 8.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 9.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Authors:  De-chu C Tang; Jianfeng Zhang; Haroldo Toro; Zhongkai Shi; Kent R Van Kampen
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

Review 10.  Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.

Authors:  Janice Kim; Robert R Hall; Maciej S Lesniak; Atique U Ahmed
Journal:  Viruses       Date:  2015-11-27       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.